Search results: (10000)
News Biosimilar Bevacizumab in Patients with Non-Small Cell Lung Cancer
Biosimilar drugs are essentially analogous to generics for biological medicines. The patent protection for the original bevacizumab product will expire in the European Union in 2022. Consequently, several companies have already embarked on developing a biosimilar molecule.
News Clinical Results of the Pinnacle Acetabular System: Data from the UK Joint Replacement Registry
The Pinnacle Acetabular System has been available on the market for nearly two decades. Since then, it has been implanted in numerous healthcare facilities worldwide. Clinical outcomes of the acetabular system were evaluated by analyzing data from the National Joint Replacement Registry of England, Wales, Northern Ireland, and the Isle of Man.
News Does Dosage Frequency Matter for Adherence to Anticholinergic Treatment in Patients with COPD?
A study by Spanish authors compared the adherence of patients with chronic obstructive pulmonary disease (COPD) to anticholinergic treatment administered once every 12 hours and once every 24 hours.
News The Link Between Various Sleep Disorders and the Onset of Depression: What Findings Did the Population Study in Denmark Bring?
A Danish population study published in June 2019 examined the link between different types of sleep disorders and the risk of developing depression. Which disorders confirmed this link after evaluating data from tens of thousands of patients?
News Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction
Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with reduced ejection fraction (HFrEF). The aim of the study presented below was to evaluate the synergistic effect of these modern medications.
News Remarkable Findings from the Subanalysis of the Efficacy and Safety of Teriflunomide in the Chinese Population with MS in Relation to Global Results
Teriflunomide, from the group of disease-modifying drugs (DMDs), intended for the treatment of patients with multiple sclerosis (MS), inhibits the proliferation of lymphocytes. As a result, fewer lymphocytes that could damage the CNS pass through the blood-brain barrier. The efficacy and safety of teriflunomide in the global population were examined in the multinational randomized double-blind placebo-controlled TOWER study, with an interesting subanalysis published by Chinese authors.
News Physical Activity in Young Men with Hemophilia A
What may influence the inclusion of physical activity in the lifestyle of individuals with hemophilia? This was the focus of a Norwegian study published in the journal Haemophilia.
News New Treatment Options for Hemophilia Come with Discussions on Important Issues
The organizing committee of this year's virtual congress of the European Association for Haemophilia and Allied Disorders (EAHAD 2021) promised in the opening speech a "showcase of the latest innovations and advances in the field of hemophilia and bleeding disorders." The program naturally included discussions on current research findings and practical experiences. Topics included the potential role of coagulation factor VIII even with non-factor therapies and the importance of monitoring the success of new therapeutic approaches.
News Model of Risk of Bleeding Associated with Physical Activity in Hemophiliacs with Factor and Non-Factor Treatment
In the treatment of hemophilia A, both FVIII concentrate replacement therapy and non-factor therapy are available today. However, there is no clinical data comparing the risk of bleeding associated with physical activity between factor and non-factor treatments. In this situation, one approach is to model possible scenarios and attempt to indirectly compare different modalities of bleeding prevention.
News New Antidiabetic Drugs in Cardiovascular Prevention in International Recommendations
Results from studies on new antidiabetic drugs showing cardiovascular (CV) benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i, gliflozins) and glucagon-like peptide 1 receptor agonists (GLP-1RA) have led to efforts to create new recommendations for their use in patients with type 2 diabetes mellitus (T2DM) for primary and secondary CV disease prevention. A recent review by American experts succinctly summarizes what current guidelines from American and European professional societies say on this subject.
News Cardiovascular Interventions with Continued Therapy with Dabigatran − Insights from the GLORIA-AF Study
An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion or atrial fibrillation ablation, pacemaker implantation, and coronary angiography with possible stent implantation.
News Fresh data from real clinical practice on targeted treatment of RA with etanercept: Should therapy be changed after 12 weeks due to insufficient response?
A recently published German study investigated, among other things, what percentage of patients with rheumatoid arthritis (RA) achieve remission or low disease activity after a certain period of etanercept treatment in real clinical practice.
News Relationship Between Mortality and Use of Statins or RAAS Inhibitors After Aortic Valve Replacement
The impact of prescribed medication after transcatheter aortic valve replacement (TAVR) has not been precisely assessed to date. A recently published retrospective analysis of clinical practice data from patients who underwent TAVR aimed to assess the potential benefit of using statins and renin-angiotensin-aldosterone system (RAAS) inhibitors.
News Study COPDGene Redefines Diagnostic Criteria of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease ranks among the top causes of morbidity and mortality worldwide. Current diagnostic criteria for the disease are based exclusively on spirometric examination. Increasing evidence, however, suggests that a significant number of patients show signs of chronic obstructive pulmonary disease without pathological findings on spirometry. The analysis of the COPDGene study thus proposes expanding the diagnostic criteria to include additional parameters.
News Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to crizotinib therapy, brigatinib administration in phase III clinical trials led to high systemic and intracranial therapeutic responses and concurrently improved median progression-free survival (PFS). The primary analysis objective of the phase II J-ALTA clinical study, presented at this year's American Society of Clinical Oncology (ASCO) congress, was to assess the efficacy and safety of therapy in patients with ALK-positive NSCLC naïve to previous ALKi therapy.
News Non-factor vs. Factor Prophylaxis of Hemophilia A: A Comparison of Cost and Treatment Effectiveness Based on Real-World Data from the USA
In the prophylactic treatment of patients with hemophilia A, particularly its severe form, concentrates of clotting factor VIII (FVIII) with extended half-life (EHL) are increasingly administered, or non-factor treatment, represented in clinical practice by FVIII mimetic antibody emicizumab. However, insights into the direct comparison of effectiveness and economic burden arising from prophylaxis with these modalities are limited, including data from real-world practice. One recently published study therefore attempted to conduct such a retrospective comparison based on data from healthcare-related databases in the USA.
News Efficacy and Safety of Dual Bronchodilator Therapy for COPD – From Randomized Clinical Trials to Real-World Clinical Practice
Dual bronchodilator therapy (LAMA + LABA) represents one of the mainstays of treating chronic obstructive pulmonary disease (COPD). The aim of the recent systematic review presented below was to assess the efficacy and safety of this dual therapy compared to monotherapy or other combinations in the context of clinical trials and real-world clinical practice.
News Is long-term treatment with ixekizumab sufficiently safe?
Psoriasis is a chronic inflammatory disease whose manifestations require long-term treatment. A poster presented at last year's European Academy of Dermatology and Venereology (EADV) congress summarizes ixekizumab safety data from monitoring lasting up to 5 years, based on nearly 18,000 patient-years (PY) in the treatment of this disease.
News New Therapeutic Options in Light of Current Knowledge on the Pathogenesis of Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense itching and recurrent eczematous lesions. AD is diagnosed in 2 out of 10 children and often persists into adulthood. In developed countries, it is the most common skin disease with a lifetime prevalence exceeding 15%. However, it is also very diverse due to a wide range of clinical phenotypes reflecting various pathophysiological mechanisms and interactions between genetics, the immune system, and the environment. So, what have we learned about atopic dermatitis from recent research, and how has this translated into advances in its treatment?
News Changes in Blood Count as Possible Prognostic Markers of Response to Panitumumab in Patients with mCRC
As part of the VALENTINO study with panitumumab in patients with metastatic colorectal cancer without RAS mutation, the connection between certain blood count parameters associated with inflammation and patient prognosis was investigated.
News Cannabidiol as a way to reduce anxiety in patients with Parkinson's disease?
A recent study by Brazilian authors examined the effects of cannabidiol on tremors and anxiety in patients with Parkinson's disease. Could it represent a promising modality in this indication?
News The Importance of Adequate Protein Intake in Critical Patients – Analysis of Data from an International Study
Adequate protein intake is a necessary part of care for critically ill patients and mitigates catabolic reactions associated with severe illness or injury. The benefits of proper determination and adherence to protein intake, however, have not been sufficiently assessed in detail. Therefore, this topic was the focus of a work analyzing data from an international observational multicenter study published in the Journal of Parenteral and Enteral Nutrition.